ClinicalTrials.gg
CompletedNCT02234843EINSTEIN JrUpdated Apr 1, 2020Results posted

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban (Xarelto, BAY59-7939) in Venous Thromboembolism, sponsored by Bayer. Completed at 109 sites in 28 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-01.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.

Enrollment
22nd of 61
500 · median 272
Started
2014
with 2 others
Phase 3
26 of 61
5 open now
Registered
19th of 61
by date
Lead sponsor
15 of 61
Bayer

Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 22nd largest by enrollment, is one of 3 that started in 2014, is one of 26 in phase 3, and was the 19th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing rivaroxaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate comparative efficacy and safety of rivaroxaban to standard of care in children with acute venous thromboembolism.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • Pediatric
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged birth to \< 18 years with confirmed venous thromboembolism who receive initial treatment with therapeutic dosages of UFH (unfractionated heparin), LMWH (low molecular weight heparin) or fondaparinux and require anticoagulant therapy for at least 90 days. However, children aged birth to \< 2 years with catheter-related thrombosis require anticoagulant therapy for at least 30 days.
  • For children younger than 6 months:

    • Gestational age at birth of at least 37 weeks.
    • Oral feeding/nasogastric/gastric feeding for at least 10 days.
    • Body weight ≥2600 g

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or bleeding risk contraindicating anticoagulant therapy
  • An estimated (eGFR) \< 30 mL/min/1.73 m*2 (in children younger than 1 year, serum creatinine results above 97.5th percentile excludes participation)
  • Hepatic disease which is associated with either: coagulopathy leading to a bleeding risk, or > 5x upper level of normal () or total > 2x ULN with direct bilirubin > 20% of the total
  • count \< 50 x 109/L
  • Sustained uncontrolled hypertension defined as > 95th age percentile
  • \< 3 months
  • Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 () and P-glycoprotein (P-gp), including but not limited to all protease inhibitors and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically
  • Concomitant use of strong inducers of CYP3A4, including but not limited to rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine
  • without proper measures, pregnancy or breast feeding
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    BAY59-7939

    Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Experimental
    Standard of Care

    Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care

    Drug: Standard of Care

Interventions

  • Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets

  • Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension

  • DrugStandard of Care

    LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy. dose : as per standard of care

06

What researchers measure

Primary outcomes

  1. Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period

    The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population

    Time frame: During the main study treatment period (i.e., 3 months, except for children with central venous catheter venous thromboembolism (CVC-VTE) aged <2 years for whom it was 1 month)

  2. Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period

    The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population

    Time frame: During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)

  3. Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During Extended Treatment Period

    Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant in the specific subgroup entered in the specific optional extension period, no analysis of an outcome was possible., The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference Population.

    Time frame: During extended treatment period: up to month 12.

  4. Number of Subjects With the Composite of All Symptomatic Recurrent Venous Thromboembolism During the 30 Days Post-study Treatment Period (i.e. >2 and ≤ 30 Days After Stop of Study Medication)

    The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Age group with primary efficacy outcome was reported.

    Time frame: More than 2 and up to 30 days after stop of study medication

  5. Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period

    The Central independent adjudication committee (CIAC) classified bleeding as: Major bleeding defined as overt bleeding and: · associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact (visit or telephone call) with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life (such as loss of school days or hospitalization).

    Time frame: During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)

  6. Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Extended Treatment Period

    Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant entered in the specific optional extension period, no analysis of an outcome was possible. The CIAC classified bleeding as: Major bleeding defined as overt bleeding and: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life.

    Time frame: During extended treatment period: up to month 12.

Secondary outcomes

  1. Incidence Rates of the Composite of All Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging During the Main Treatment Period

    The secondary efficacy outcome defined as the composite of all symptomatic recurrent venous thromboembolism and asymptomatic deterioration on repeat imaging as assessed by central independent adjudication committee. (CIAC) Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population

    Time frame: During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)

  2. AUC(0-24)ss in Plasma

    AUC(0-24)ss: Area under the concentration vs. time curve from time 0 to 24 hours at steady state.

    Time frame: over 24 hours

  3. Cmax,ss in Plasma

    Maximum drug concentration in measured matrix at steady state during a dosage interval

    Time frame: 0 hours to 24 hours, 0 hours to 12 hours or 0 hours to 8 hours (one dosing interval in steady state)

  4. Ctrough,ss in Plasma

    Ctrough,ss refers to the drug concentration at the end of the dosage interval at steady state

    Time frame: 0 hours to 24 hours, 0 hours to 12 hours or 0 hours to 8 hours(one sampling interval in steady state)

  5. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

    Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60

  6. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

    Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60

  7. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

    Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60

  8. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

    Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60

  9. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

    Time frame: Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60

  10. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

    Time frame: Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60

  11. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

    Time frame: Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60

  12. Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years

    Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

    Time frame: Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60

  13. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

    Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60

  14. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

    Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60

  15. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

    Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60

  16. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

    Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60

  17. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

    Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60

  18. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

    Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60

  19. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

    Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60

  20. Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years

    The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

    Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60

  21. Anti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

    Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 24 hours on Day 90

  22. Anti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

    Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 24 hours on Day 90

  23. Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

    Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 16 hours on Day 90

  24. Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

    Time frame: Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 16 hours on Day 90

  25. Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.

    Time frame: Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60

  26. Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.

    Time frame: Up to 3 hours post dose on Day 30, up to 6 hours post dose on Day 60, and up to 16 hours on Day 90

  27. Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.

    Time frame: Up to 3 hours post dose on Day 30, up to 6 hours post dose on Day 60, up to 16 hours on Day 90 and follow-up up to 30 days

  28. Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years

    This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

    Time frame: Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60

07

Results

Posted Apr 1, 2020

Participant flow

Study was conducted at 109 study centers in 28 countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Portugal, Russia, Singapore, Slovakia, Spain, Sweden, Switzerland, Turkey, UK, and USA between 13 Nov 2014 and 30 Jan 2019.

Participant flow — Overall Study
MilestoneRivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 12-<18Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5
Started1846747211692342298
Completed1626144161479322088
Not completed226352132210
Withdrew: Death1000000000
Withdrew: Protocol violation1010000000
Withdrew: Efficacy outcome reached2000020000
Withdrew: Patient convenience2000010000
Withdrew: Withdrawal by subject5110070000
Withdrew: Recovery1000000000
Withdrew: Other0201010100
Withdrew: Physician decision4101000100
Withdrew: Adverse event5113210010
Withdrew: Non-compliance with study drug1000011000
Withdrew: Lost to follow-up0100001000

Outcome measures

PrimaryIncidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period

The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population

Time frame:
During the main study treatment period (i.e., 3 months, except for children with central venous catheter venous thromboembolism (CVC-VTE) aged <2 years for whom it was 1 month)
Reported as:
Number · Percentage of participants
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period
Percentage of participantsRivaroxaban GroupComparator Group
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period1.2 (0.4 to 3.0)3.0 (1.2 to 6.6)
Statistical analysis
  • Rivaroxaban Group vs Comparator Group · Expl. Cox Proportional Hazards Model · p = 0.1509 · Hazard ratio (hr): 0.4 · 95% CI 0.11 to 1.41
PrimaryIncidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period

The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population

Time frame:
During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)
Reported as:
Number · Percentage of participants
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period
Percentage of participantsRivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 12-<18Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period2.2 ± 0.70.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.03.3 ± 0.92.9 ± 0.24.5 ± 0.20.0 ± 0.00.0 ± 0.0
PrimaryIncidence Rates of All Symptomatic Recurrent Venous Thromboembolism During Extended Treatment Period

Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant in the specific subgroup entered in the specific optional extension period, no analysis of an outcome was possible., The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference Population.

Time frame:
During extended treatment period: up to month 12.
Reported as:
Number · Percentage of participants
Incidence Rates of All Symptomatic Recurrent Venous Thromboembolism During Extended Treatment Period
Percentage of participantsRivaroxaban, Aged 12-<18Comparator, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5
Extension 1 (month 3 to 6)0.0 (0.0 to 3.8)2.2 (0.1 to 10.9)0.0 (0.0 to 14.6)0.0 (0.0 to 16.3)—0.0 (0.0 to 77.6)0.0 (0.0 to 14.6)0.0 (0.0 to 37.7)0.0 (0.0 to 95.0)0.0 (0.0 to 95.0)
Extension 2 (month 6 to 9)2.6 (0.1 to 13.4)5.3 (0.3 to 24.4)0.0 (0.0 to 29.9)0.0 (0.0 to 40.2)——0.0 (0.0 to 63.2)0.0 (0.0 to 77.6)——
Extension 3 (month 9 to 12)0.0 (0.0 to 11.6)0.0 (0.0 to 23.0)0.0 (0.0 to 63.2)0.0 (0.0 to 77.6)——0.0 (0.0 to 95.2)0.0 (0.0 to 77.6)——
PrimaryNumber of Subjects With the Composite of All Symptomatic Recurrent Venous Thromboembolism During the 30 Days Post-study Treatment Period (i.e. >2 and ≤ 30 Days After Stop of Study Medication)

The Central independent adjudication committee (CIAC) classified symptomatic recurrent venous thromboembolism (VTE). Age group with primary efficacy outcome was reported.

Time frame:
More than 2 and up to 30 days after stop of study medication
Reported as:
Count of participants · Participants
Number of Subjects With the Composite of All Symptomatic Recurrent Venous Thromboembolism During the 30 Days Post-study Treatment Period (i.e. >2 and ≤ 30 Days After Stop of Study Medication)
ParticipantsRivaroxaban, Aged 12-<18Comparator, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5
Number of Subjects With the Composite of All Symptomatic Recurrent Venous Thromboembolism During the 30 Days Post-study Treatment Period (i.e. >2 and ≤ 30 Days After Stop of Study Medication)0200000000
PrimaryIncidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period

The Central independent adjudication committee (CIAC) classified bleeding as: Major bleeding defined as overt bleeding and: · associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact (visit or telephone call) with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life (such as loss of school days or hospitalization).

Time frame:
During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)
Reported as:
Number · Percentage of participants
Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period
Percentage of participantsRivaroxaban GroupComparator Group
Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period3 (1.6 to 5.5)1.9 (0.5 to 3.3)
PrimaryIncidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period

The Central independent adjudication committee (CIAC) classified bleeding as: Major bleeding defined as overt bleeding and: · associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact (visit or telephone call) with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life (such as loss of school days or hospitalization).

Time frame:
During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)
Reported as:
Number · Percentage of participants
Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period
Percentage of participantsRivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 12-<18Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5
Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Main Treatment Period1.7 ± 0.53.0 ± 0.56.5 ± 1.84.8 ± 0.26.7 ± 0.32.2 ± 0.40.0 ± 0.00.0 ± 0.011.1 ± 0.60.0 ± 0.0
PrimaryIncidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Extended Treatment Period

Incidence rates for all children except those aged \< 2 years with catheter-related thrombosis. If no participant entered in the specific optional extension period, no analysis of an outcome was possible. The CIAC classified bleeding as: Major bleeding defined as overt bleeding and: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death. Clinically relevant non-major bleeding defined as overt bleeding not meeting the criteria for major bleeding, but associated with: medical intervention, or unscheduled contact with a physician, or (temporary) cessation of study treatment, or discomfort for the child such as pain or impairment of activities of daily life.

Time frame:
During extended treatment period: up to month 12.
Reported as:
Number · Percentage of participants
Incidence Rates of the Composite of Treatment Emergent Overt Major Bleeding and Clinically Relevant Non-major (CRNM) Bleeding During Extended Treatment Period
Percentage of participantsRivaroxaban, Aged 12-<18Rivaroxaban, Aged 0.5-<2Comparator, Aged 12-<18Comparator, Aged 0.5-<2Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged Birth-<0.5Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged Birth-<0.5
Extension 1 (month 3 to 6)1.1 (0.1 to 5.3)—0.0 (0.0 to 6.9)0.0 (0.0 to 95.0)0.0 (0.0 to 14.6)0.0 (0.0 to 16.3)0.0 (0.0 to 77.6)0.0 (0.0 to 34.9)0.0 (0.0 to 37.7)0.0 (0.0 to 95.0)
Extension 2 (month 6 to 9)2.6 (0.1 to 13.4)—5.3 (0.3 to 24.4)—0.0 (0.0 to 29.9)0.0 (0.0 to 40.2)—0.0 (0.0 to 63.2)0.0 (0.0 to 77.6)—
Extension 3 (month 9 to 12)0.0 (0.0 to 11.6)—0.0 (0.0 to 23.0)—0.0 (0.0 to 63.2)0.0 (0.0 to 77.6)—0.0 (0.0 to 95.0)0.0 (0.0 to 77.6)—
SecondaryIncidence Rates of the Composite of All Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging During the Main Treatment Period

The secondary efficacy outcome defined as the composite of all symptomatic recurrent venous thromboembolism and asymptomatic deterioration on repeat imaging as assessed by central independent adjudication committee. (CIAC) Incidence = number of events / number at risk, where: number of events = number of subjects having the event in the time window. number at risk = number of subjects in reference population

Time frame:
During the main study treatment period (i.e., 3 months, except for children with CVC-VTE aged <2 years for whom it was 1 month)
Reported as:
Number · Percentage of participants
Incidence Rates of the Composite of All Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging During the Main Treatment Period
Percentage of participantsRivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 12-<18Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5
Incidence Rates of the Composite of All Symptomatic Recurrent Venous Thromboembolism and Asymptomatic Deterioration in Thrombotic Burden on Repeat Imaging During the Main Treatment Period2.2 ± 0.70.0 ± 0.02.1 ± 0.10.0 ± 0.00.0 ± 0.04.3 ± 1.52.9 ± 0.24.5 ± 0.20.0 ± 0.00.0 ± 0.0
SecondaryAUC(0-24)ss in Plasma

AUC(0-24)ss: Area under the concentration vs. time curve from time 0 to 24 hours at steady state.

Time frame:
over 24 hours
Reported as:
Geometric mean · microgram*hour per liter
AUC(0-24)ss in Plasma
microgram*hour per literRivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5
AUC(0-24)ss in Plasma2120 ± 26.41960 ± 31.72380 ± 40.71840 ± 36.41590 ± 29.6
SecondaryCmax,ss in Plasma

Maximum drug concentration in measured matrix at steady state during a dosage interval

Time frame:
0 hours to 24 hours, 0 hours to 12 hours or 0 hours to 8 hours (one dosing interval in steady state)
Reported as:
Geometric mean · microgram per liter
Cmax,ss in Plasma
microgram per literRivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5
Cmax,ss in Plasma237 ± 20.6184 ± 36.2182 ± 31.2136 ± 29.4119 ± 24.1
SecondaryCtrough,ss in Plasma

Ctrough,ss refers to the drug concentration at the end of the dosage interval at steady state

Time frame:
0 hours to 24 hours, 0 hours to 12 hours or 0 hours to 8 hours(one sampling interval in steady state)
Reported as:
Geometric mean · microgram per liter
Ctrough,ss in Plasma
microgram per literRivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5
Ctrough,ss in Plasma20.7 ± 45.821.4 ± 62.731.6 ± 70.122.9 ± 68.618.5 ± 50.4
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

Time frame:
Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years
ratioRivaroxaban, Aged 12-<18
Day 30 (0.5-1.5h) n=1561.29 ± 0.28
Day 30 (2.5-4h) n=1501.57 ± 0.36
Day 60 (2-8h) n=1561.52 ± 0.29
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

Time frame:
Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years
ratioRivaroxaban, Aged 6-<12
Day 30 (0.5-1.5h) n=181.46 ± 0.25
Day 30 (2.5-4h) n=201.67 ± 0.39
Day 60 (2-8h) n=201.52 ± 0.33
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

Time frame:
Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years
ratioRivaroxaban, Aged 6-<12
Day 30 (0.5-1.5h) n=331.17 ± 0.23
Day 30 (2.5-4h) n=331.26 ± 0.22
Day 60 (2-8h) n=341.21 ± 0.19
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

Time frame:
Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years
ratioRivaroxaban, Aged 2-<6
Day 30 (0.5-1.5h) n=10.99 ± NA
Day 30 (2.5-4h) n=341.36 ± 0.28
Day 60 (2-8h) n=321.33 ± 0.26
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

Time frame:
Up to 4 hours post dose on Day30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years
ratioRivaroxaban, Aged 0.5-<2
Day 30 (2.5-4h) n=11.41 ± NA
Day 60 (2-8h) n=21.05 ± 0.17
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

Time frame:
Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60
Reported as:
Mean · ratio
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years
ratioRivaroxaban, Aged 2-<6
Day 30 (0.5-3h) n=41.87 ± 1.09
Day 60 (2-6h) n=41.32 ± 0.12
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

Time frame:
Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60
Reported as:
Mean · ratios
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years
ratiosRivaroxaban, Aged 0.5-<2
Day 30 (0.5-3h) n=91.25 ± 0.18
Day 60 (2-6h) n=72.00 ± 2.22
SecondaryProthrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years

Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds.

Time frame:
Up to 3 hours post dose on Day30, and up to 6 hours post dose on Day 60
Reported as:
Mean · ratio
Prothrombin Time (PT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years
ratioRivaroxaban, Aged Birth-<0.5
Day 30 (0.5-3h) n=111.35 ± 0.20
Day 60 (2-6h) n=41.45 ± 0.16
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

Time frame:
Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years
ratioRivaroxaban, Aged 12-<18
Day 30 (0.5-1.5h) n=1541.17 ± 0.28
Day 30 (2.5-4h) n=1491.38 ± 0.50
Day 60 (2-8h) n=1531.33 ± 0.38
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

Time frame:
Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years
ratioRivaroxaban, Aged 6-<12
Day 30 (0.5-1.5h) n=171.27 ± 0.20
Day 30 (2.5-4h) n=171.39 ± 0.26
Day 60 (2-8h) n=191.24 ± 0.20
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

Time frame:
Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years
ratioRivaroxaban, Aged 6-<12
Day 30 (0.5-1.5h) n=301.11 ± 0.24
Day 30 (2.5-4h) n=301.15 ± 0.22
Day 60 (2-8h) n=311.18 ± 0.24
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

Time frame:
Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years
ratioRivaroxaban, Aged 2-<6
Day 30 (0.5-1.5h) n=10.90 ± NA
Day 30 (2.5-4h) n=321.29 ± 0.33
Day 60 (2-8h) n=291.23 ± 0.21
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds. 'NA' denotes the data that cannot be calculated.

Time frame:
Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years
ratioRivaroxaban, Aged 0.5-<2
Day 30 (2.5-4h) n=11.13 ± NA
Day 60 (2-8h) n=21.10 ± 0.02
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

Time frame:
Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years
ratioRivaroxaban, Aged 2-<6
Day 30 (0.5-3h) n=41.50 ± 0.83
Day 60 (2-6h) n=41.13 ± 0.06
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

Time frame:
Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years
ratioRivaroxaban, Aged 0.5-<2
Day 30 (0.5-3h) n=91.20 ± 0.39
Day 60 (2-6h) n=61.10 ± 0.47
SecondaryActivated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years

The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V,VIII, IX, X, XI and XII. The initial read-out is in seconds.

Time frame:
Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Reported as:
Mean · ratio
Activated Partial Thromboplastin Time (aPTT) Ratios to Baseline: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years
ratioRivaroxaban, Aged Birth-<0.5
Day 30 (0.5-3h) n=91.31 ± 0.15
Day 60 (2-6h) n=31.21 ± 0.16
SecondaryAnti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

Time frame:
Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 24 hours on Day 90
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 12-<18 Years
microgram per liter (mcg/L)Rivaroxaban, Aged 12-<18
Day 30 (0.5-1.5h) n=141164.46 ± 124.46
Day 30 (2.5-4h) n=164254.66 ± 188.64
Day 60 (2-8h) n=167255.40 ± 171.59
Day 90 (20-24h) n=5862.12 ± 175.87
SecondaryAnti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

Time frame:
Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 24 hours on Day 90
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Once Daily (Suspension and Tablet) in the Age Group 6-<12 Years
microgram per liter (mcg/L)Rivaroxaban, Aged 6-<12
Day 30 (0.5-1.5h) n=22206.89 ± 105.01
Day 30 (2.5-4h) n=23263.24 ± 156.73
Day 60 (2-8h) n=22243.45 ± 124.92
Day 90 (20-24h) n=927.39 ± 14.66
SecondaryAnti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

Time frame:
Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 16 hours on Day 90
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension and Tablet) in the Age Group 6-<12 Years
microgram per liter (mcg/L)Rivaroxaban, Aged 6-<12
Day 30 (0.5-1.5h) n=3796.82 ± 76.77
Day 30 (2.5-4h) n=36139.10 ± 102.19
Day 60 (2-8h) n=35126.53 ± 81.78
Day 90 (10-16h) n=2047.49 ± 66.88
SecondaryAnti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

Time frame:
Up to 4 hours post dose on Day 30, up to 8 hours post dose on Day 60, and up to 16 hours on Day 90
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 2-<6 Years
microgram per liter (mcg/L)Rivaroxaban, Aged 2-<6
Day 30 (2.5-4h) n=37177.78 ± 147.29
Day 60 (2-8h) n=36150.03 ± 95.77
Day 90 (10-16h) n=1854.40 ± 51.52
SecondaryAnti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.

Time frame:
Up to 4 hours post dose on Day 30, and up to 8 hours post dose on Day 60
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Twice Daily (Suspension) in the Age Group 0.5-<2 Years
microgram per liter (mcg/L)Rivaroxaban, Aged 0.5-<2
Day 30 (0.5-1.5h) n=1247.54 ± NA
Day 30 (2.5-4h) n=2160.71 ± 153.84
Day 60 (2-8h) n=4121.09 ± 81.94
SecondaryAnti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.

Time frame:
Up to 3 hours post dose on Day 30, up to 6 hours post dose on Day 60, and up to 16 hours on Day 90
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 2-<6 Years
microgram per liter (mcg/L)Rivaroxaban, Aged 2-<6
Day 30 (0.5-3h) n=4209.67 ± 127.86
Day 60 (2-6h) n=4140.46 ± 78.82
Day 90 (10-16h) n=162.56 ± NA
SecondaryAnti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method. 'NA' denotes the data that cannot be calculated.

Time frame:
Up to 3 hours post dose on Day 30, up to 6 hours post dose on Day 60, up to 16 hours on Day 90 and follow-up up to 30 days
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group 0.5-<2 Years
microgram per liter (mcg/L)Rivaroxaban, Aged 0.5-<2
Day 30 (0.5-3h) n=12111.35 ± 97.03
Day 30 (2-6h) n=11147.24 ± 125.40
Day 90 (10-16h) n=323.40 ± 4.51
Follow-up n=171.30 ± NA
SecondaryAnti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years

This is a method for measuring the inhibition of Factor Xa activity determined by an ex vivo using a photometric method.

Time frame:
Up to 3 hours post dose on Day 30, and up to 6 hours post dose on Day 60
Reported as:
Mean · microgram per liter (mcg/L)
Anti-Xa Values: Rivaroxaban Administered Three Times Daily (Suspension) in the Age Group Birth-<0.5 Years
microgram per liter (mcg/L)Rivaroxaban, Aged Birth-<0.5
Day 30 (0.5-3h) n=10118.12 ± 82.08
Day 60 (2-6h) n=5228.03 ± 181.08

Adverse events

Collected over After randomization until last intake of study medication plus 2 days, up to 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Comparator Group0/162 (0%)35/162 (21.6%)121/162 (74.7%)
Rivaroxaban Group2/329 (0.6%)78/329 (23.7%)275/329 (83.6%)
Most frequent serious events
Showing 10 of 129
Most frequent serious events
EventComparator GroupRivaroxaban Group
Febrile neutropeniaBlood and lymphatic system disorders1/1628/329
HeadacheNervous system disorders3/1622/329
VomitingGastrointestinal disorders0/1626/329
PyrexiaGeneral disorders2/1626/329
SeizureNervous system disorders2/1621/329
Abdominal painGastrointestinal disorders1/1623/329
Pain in extremityMusculoskeletal and connective tissue disorders0/1623/329
PancytopeniaBlood and lymphatic system disorders1/1620/329
Sickle cell anaemia with crisisBlood and lymphatic system disorders1/1620/329
Atrial tachycardiaCardiac disorders1/1620/329
Most frequent other events
Showing 10 of 541
Most frequent other events
EventComparator GroupRivaroxaban Group
HeadacheNervous system disorders24/16256/329
EpistaxisRespiratory, thoracic and mediastinal disorders20/16240/329
PyrexiaGeneral disorders14/16237/329
VomitingGastrointestinal disorders13/16236/329
NasopharyngitisInfections and infestations10/16229/329
DiarrhoeaGastrointestinal disorders11/16225/329
Pain in extremityMusculoskeletal and connective tissue disorders9/16223/329
CoughRespiratory, thoracic and mediastinal disorders11/16218/329
NauseaGastrointestinal disorders6/16222/329
FatigueGeneral disorders6/16221/329

Baseline characteristics

Age, Customized
Age, Customized(Participants)Rivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 12-<18Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5Total
12-<18 years1840000920000276
6-<12 years067000034000101
2-<6 years00470000220069
0.5-<2 years0002100009030
Birth-<0.5 years0000160000824
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 12-<18Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5Total
Female9724241055515951245
Male874323111137191347255
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rivaroxaban, Aged 12-<18Rivaroxaban, Aged 6-<12Rivaroxaban, Aged 2-<6Rivaroxaban, Aged 0.5-<2Rivaroxaban, Aged Birth-<0.5Comparator, Aged 12-<18Comparator, Aged 6-<12Comparator, Aged 2-<6Comparator, Aged 0.5-<2Comparator, Aged Birth-<0.5Total
Hispanic or Latino1645842151279261986429
Not Hispanic or Latino751316510029
Unknown or Not Reported1344337321242
08

Study locations

109 sites
  • Phoenix, Arizona 85016, United States
  • Little Rock, Arkansas 72202-3500, United States
  • Los Angeles, California 90027-6089, United States
  • Los Angeles, California 90095, United States
  • San Diego, California 92123, United States
  • Gainesville, Florida 32610, United States
  • Jacksonville, Florida 32207, United States
  • Miami, Florida 33155, United States
  • Pensacola, Florida 32504, United States
  • Saint Petersburg, Florida 33701, United States
  • Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60611, United States
  • Indianapolis, Indiana 46202, United States
  • Lansing, Michigan 48912, United States
  • Kansas City, Missouri 64108-9898, United States
  • Durham, North Carolina 27710, United States
  • Cincinnati, Ohio 45229-3039, United States
  • Cleveland, Ohio 44106-2602, United States
  • Columbus, Ohio 43205-2696, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Dallas, Texas 75235, United States
  • Fort Worth, Texas 76104, United States
  • Houston, Texas 77030, United States
  • San Miguel de Tucumán, Tucuman 4000, Argentina
  • Parkville, Victoria 3052, Australia
  • South Brisbane, 4101, Australia
  • Linz, Oberösterreich 4020, Austria
  • Graz, Steiermark 8036, Austria
  • Innsbruck, Tirol 6020, Austria
  • Wien, 1090, Austria
  • Bruxelles - Brussel, 1200, Belgium
  • Edegem, 2650, Belgium
  • Leuven, 3000, Belgium
  • Campinas, Sao Paulo 13083-970, Brazil
  • São Paulo, Sao Paulo 01227-200, Brazil
  • Sao Paulo, 04023-061, Brazil
  • Sao Paulo, 05403-000, Brazil
  • Calgary, Alberta T3B 6A8, Canada
  • Edmonton, Alberta T6G 2B7, Canada
  • Hamilton, Ontario L8N 3Z5, Canada
  • Ottawa, Ontario K1H 8L1, Canada
  • Toronto, Ontario M5G 1X8, Canada
  • Montreal, Quebec H4A 3J1, Canada
  • Hangzhou, Zhejiang, China
  • Beijing, 100034, China
  • Beijing, 100045, China
  • Shanghai, China
  • Turku, 20520, Finland
  • Montpellier, 34059, France
  • Paris, 75015, France
  • TOULOUSE Cedex 9, 31059, France
  • Erlangen, Bayern 91054, Germany
  • Halle, Sachsen-Anhalt 06120, Germany
  • Dresden, Sachsen 01307, Germany
  • Berlin, 13353, Germany
  • Hong Kong, Hong Kong
  • Budapest, 1097, Hungary
  • Crumlin, Dublin 12, Ireland
  • Afula, 1834111, Israel
  • Jerusalem, 9112001, Israel
  • Petach Tikva, 4920235, Israel
  • Ramat Gan, 5262000, Israel
  • Milano, Lombardia 20122, Italy
  • Torino, Piemonte 10126, Italy
  • Padova, Veneto 35128, Italy
  • Obu, Aichi 474-8710, Japan
  • Azumino, Nagano 399-8288, Japan
  • Bunkyo-ku, Tokyo 113-8655, Japan
  • Ciudad de México, Distrito Federal 06720, Mexico
  • Guadalajara, Jalisco, Mexico
  • Amsterdam, 1105 AZ, Netherlands
  • Groningen, 9713 GZ, Netherlands
  • Nijmegen, 6525 GA, Netherlands
  • Rotterdam, 3015 CE, Netherlands
  • Utrecht, 3584 CX, Netherlands
  • Carnaxide, Lisboa 2795-53, Portugal
  • Kazan, 420138, Russian Federation
  • Kemerovo, 650002, Russian Federation
  • Krasnodar, 350013, Russian Federation
  • Moscow, 117997, Russian Federation
  • Moscow, 119049, Russian Federation
  • Nizhny Novgorod, 603136, Russian Federation
  • Sankt-Peterburg, 197110, Russian Federation
  • St. Petersburg, 197022, Russian Federation
  • Volgograd, 400138, Russian Federation
  • Yekaterinburg, 620028, Russian Federation
  • Singapore, 119228, Singapore
  • Singapore, 229 899, Singapore
  • Bratislava, 833 41, Slovakia
  • Esplugues de LLobregat, Barcelona 08950, Spain
  • A Coruña, 15006, Spain
  • Barcelona, 08035, Spain
  • Solna, 171 64, Sweden
  • Bern, 3010, Switzerland
  • Luzern, 6000, Switzerland
  • Zürich, 8032, Switzerland
  • Adana, 01130, Turkey
  • Istanbul, 34093, Turkey
  • Konya, 42080, Turkey
  • Newcastle Upon Tyne, Tyne And Wear NE1 4LP, United Kingdom

Showing the first 100 of 109 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Palumbo JS, Lensing AWA, Brandao LR, Hooimeijer HL, Kenet G, van Ommen H, Pap AF, Majumder M, Kubitza D, Thelen K, Willmann S, Prins MH, Monagle P, Male C. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv. 2022 Nov 22;6(22):5821-5828. doi: 10.1182/bloodadvances.2022008160. PubMed 36006613 ↗
  • Connor P, Sanchez van Kammen M, Lensing AWA, Chalmers E, Kallay K, Hege K, Simioni P, Biss T, Bajolle F, Bonnet D, Grunt S, Kumar R, Lvova O, Bhat R, Van Damme A, Palumbo J, Santamaria A, Saracco P, Payne J, Baird S, Godder K, Labarque V, Male C, Martinelli I, Morales Soto M, Motwani J, Shah S, Hooimeijer HL, Prins MH, Kubitza D, Smith WT, Berkowitz SD, Pap AF, Majumder M, Monagle P, Coutinho JM. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020 Dec 22;4(24):6250-6258. doi: 10.1182/bloodadvances.2020003244. PubMed 33351120 ↗
  • Thom K, Lensing AWA, Nurmeev I, Bajolle F, Bonnet D, Kenet G, Massicotte MP, Karakas Z, Palumbo JS, Saracco P, Amedro P, Chain J, Chan AK, Ikeyama T, Lam JCM, Gauger C, Pap AF, Majumder M, Kubitza D, Smith WT, Berkowitz SD, Prins MH, Monagle P, Young G, Male C. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv. 2020 Oct 13;4(19):4632-4639. doi: 10.1182/bloodadvances.2020002637. PubMed 33002131 ↗
  • Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaria A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kallay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan;7(1):e18-e27. doi: 10.1016/S2352-3026(19)30219-4. Epub 2019 Nov 5. PubMed 31699660 ↗
  • Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaria A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Gottl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13. PubMed 31420317 ↗
  • Lensing AWA, Male C, Young G, Kubitza D, Kenet G, Patricia Massicotte M, Chan A, Molinari AC, Nowak-Goettl U, Pap AF, Adalbo I, Smith WT, Mason A, Thelen K, Berkowitz SD, Crowther M, Schmidt S, Price V, Prins MH, Monagle P. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thromb J. 2018 Dec 21;16:34. doi: 10.1186/s12959-018-0188-y. eCollection 2018. PubMed 30598642 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jan 2019, 50 months.

Results were first posted in Apr 2020, 1 year 2 months after primary completion.

Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2014
First posted
Sep 9, 2014
StartActual
Nov 13, 2014
Primary completionActual
Jan 30, 2019
CompletionActual
Jan 30, 2019
Results first posted
Apr 1, 2020
Last update
Apr 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02234843
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 9, 2014
Start date
Nov 13, 2014
Primary completion
Jan 30, 2019
Completion
Jan 30, 2019
Results posted
Apr 1, 2020
Last update
Apr 1, 2020

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion